NCT04912427View on ClinicalTrials.gov

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 6, 2022

Study Completion Date

January 26, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Isatuximab

Isatuximab is supplied by Sanofi.

DRUG

Bortezomib

Bortezomib is commercially available.

DRUG

Dexamethasone

Dexamethasone is commercially available.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04912427 - Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | Biotech Hunter | Biotech Hunter